A phase III, randomized, study of weekly Taxoprexin [DHA paclitaxel] plus carboplatin versus paclitaxel plus carboplatin as first line chemotherapy in patients with advanced non-small cell lung cancer
Phase of Trial: Phase III
Latest Information Update: 28 Jan 2018
At a glance
- Drugs DHA-paclitaxel (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Luitpold Pharmaceuticals
- 12 Jan 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 Oct 2006 New trial record.